Terazosin Hydrochloride Capsule
Product Images NDC 68788-9816

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 68788-9816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

59746 383 06

Terazosin Hydrochloride Capsules 1 mg label showing the product name, dosage form, and strength as generic for Hytrin. The label includes manufacturer information, Jubilant Cadista Pharmaceuticals, and storage instructions. It features English and Spanish dosing directions to take tablets daily as directed by a doctor. The label is from Preferred Pharmaceuticals, Inc.*

FDA Label Image

59746 384 06

Terazosin Hydrochloride Capsules 2 mg packaging label showing the product name, generic indication for Hytrin, and manufacturer Jubilant Cadista Pharmaceuticals Inc. The label includes storage instructions, caution statements, and dispensing directions in English and Spanish. A barcode and QR code are visible, along with spaces for filling in package size, expiration date, lot number, batch number, and insurance details. The labeler is Preferred Pharmaceuticals, Inc.*

FDA Label Image

59746 385 06

Terazosin Hydrochloride Capsules 5 mg label showing the generic name and strength. The label indicates it is generic for Hytrin, includes storage instructions, and lists Jubilant Cadista Pharmaceuticals as the manufacturer. Directions are provided in English and Spanish on a yellow background. The label displays the Preferred Pharmaceuticals, Inc. logo and includes warnings, lot number, expiration date, and barcode.*

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin hydrochloride, showing its molecular composition and arrangement including aromatic rings, amine group, piperazine ring, and hydrochloride component.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

A set of two line graphs comparing placebo and terazosin treatment over three months. The first graph shows the mean change in total symptom score from baseline, with scores decreasing more in the terazosin group. The second graph shows the mean increase in peak flow rate from baseline, with greater increases observed in the terazosin group compared to placebo over time.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph depicting mean change from baseline over a 30-month period. The x-axis represents months, marked at various intervals, and the y-axis shows mean change values. Data points are connected with a line, and some points are marked with an asterisk indicating significance.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph showing mean change from baseline in mL/second over a 30-month period. The x-axis represents time in months from 0 to 30, while the y-axis measures mean change. Data points are connected with lines and marked with asterisks indicating statistical significance at several time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.